-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bortezomib, lenalidomide, and dexamethasone combined with stem cell transplantation are the standard treatments for eligible patients with multiple myeloma
.
Because remission can deepen over time, longer and more effective induction/consolidation phases are needed
stem cell
This is a phase 2 clinical trial that recruits patients with multiple myeloma who can be transplanted to receive carfilzomib (K) 20/36 mg/m2 (days 1-2/8-9/15-16) , Lenalidomide (R) 25 mg (day 1-21) and dexamethasone (d) 20 mg (day 1-2/8-9/15-16/22-23) treatment, 28 days Course of treatment
.
All patients underwent bone marrow transplantation after 4 courses and received lenalidomide (10 mg, day 1-21) for maintenance treatment for one year
Can assess the patient's remission
Can assess the patient's remissionOverall, 48 patients were screened and 46 of them were recruited into the group; 21% of patients had poor cytogenetics
.
Among the 42 patients who could be evaluated after consolidation therapy, 26 achieved complete remission under strict conditions (CR 61.
Screening Among 42 patients who could be evaluated after consolidation treatment, 26 achieved complete remission under strict conditions (CR 61.
Progression-free survival rate of patients with different MRD status
Progression-free survival rate of patients with different MRD statusThe median time to obtain CR was 10.
6 months
.
According to multi-parameter flow cytometry and next-generation sequencing technology, 69.
At a median follow-up of 60.
Heart blood vessels of heart failure thrombosis infection
All in all, 8 courses of KRd treatment can achieve rapid and profound remission in newly diagnosed multiple myeloma patients who are eligible for transplantation , and the safety is acceptable, but cardiovascular adverse events need to be closely monitored
8 courses of KRd treatment can obtain rapid and profound remission for newly diagnosed multiple myeloma patients who are eligible for transplantation , and the safety is acceptable, but it is necessary to closely monitor cardiovascular adverse events.
Original source:
Murielle Roussel, et al.
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results in this message
